|
HS Code |
138681 |
| Chemical Name | 1-Pyrrolidinecarboxylic acid, 3-Amino-4-Hydroxy-, 1,1-Dimethylethyl ester, (3S,4S)- |
As an accredited 1-Pyrrolidinecarboxylicacid,3-Amino-4-Hydroxy-,1,1-Dimethylethylester,(3S,4S)- factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of (3S,4S)-3 - Amino - 4 - Hydroxy - 1 - Pyrrolidinecarboxylic acid 1,1 - Dimethylethylester in sealed chemical - grade packaging. |
| Shipping | The chemical "1 - Pyrrolidinecarboxylic acid, 3 - Amino - 4 - Hydroxy -, 1,1 - Dimethylethylester, (3S,4S)-" is shipped in accordance with strict chemical transportation regulations. It's packaged securely to prevent spills, with proper labeling for safety during transit. |
| Storage | 1-(tert -Butyl) 3 -amino -4 -hydroxy -L -prolinate should be stored in a cool, dry place, away from direct sunlight. Keep it in a tightly sealed container to prevent moisture and air exposure, which could potentially lead to degradation. Store it separately from incompatible substances, as it may react with certain chemicals. Recommended storage temperature is typically around 2 - 8°C in a refrigerator for long - term stability. |
In the commercial synthesis of macrocyclic HCV NS3/4A protease inhibitors such as danoprevir sodium and glecaprevir, the (3S,4S)-3-amino-4-hydroxypyrrolidine-1-carboxylic acid *tert*-butyl ester serves as the stereodefined P2 cap precursor. Loading factors in the pivotal amide coupling step range from 1.05 to 1.15 molar equivalents relative to the macrocyclic acid intermediate; the excess is calibrated to compensate for competing hydrolysis of the activated ester under aqueous workup conditions, with lot-to-lot adjustments based on the water content of the dimethylformamide co-solvent determined by Karl Fischer titration (≤ 200 ppm). The downstream manufacturing sequence couples the (3S,4S)-subunit to a quinoline- or difluoromethyl-substituted macrocycle using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and 1-hydroxybenzotriazole in a dichloromethane/dimethylformamide 4:1 v/v mixture maintained at −5 °C to +5 °C; exotherm is managed in a glass-lined jacketed vessel with retreat-curve impeller and jacket setpoint capable of ramping from −20 °C. After liquid-liquid extraction and brine wash, the organic phase is concentrated under reduced pressure (≤ 100 mbar, jacket ≤ 35 °C) and the Boc protecting group is cleaved with anhydrous HCl in isopropyl acetate or trifluoroacetic acid at a controlled internal temperature of 0–5 °C, liberating the hydrochloride salt of the free amino-alcohol. The rate of HCl gas addition is indexed to the heat-flow signal measured by a reaction calorimeter to keep the instantaneous power release below 25 W/L, preventing the thermal runaway that accelerates oxazolidinone side-product formation—a path that erodes yield by 8–12% and requires an additional hot-filtration step through a 0.5 µm sintered metal candle filter to remove insoluble polymeric debris. The crude hydrochloride is crystallized from ethyl acetate/n-heptane 1:3 v/v at −10 °C, filtered under nitrogen pressure, and dried in a double-cone rotary vacuum dryer at 40 °C jacket temperature and internal pressure ≤ 5 mbar until loss on drying falls below 0.5% w/w. Chiral purity is verified by HPLC on a Chiralpak IA-3 column (4.6 × 250 mm, 5 µm) with n-hexane/ethanol/diethylamine 80/20/0.1 at 1.0 mL/min; acceptance criterion is enantiomeric excess ≥ 99.5%, and any batch falling below 99.0% is rejected for GMP campaigns. Regulatory structure for the intermediate and resulting API follows ICH Q7 active pharmaceutical ingredient GMPs, with residual solvent profiles controlled against ICH Q3C and elemental impurities risk-assessed per ICH Q3D using permitted daily exposure values for palladium (≤ 10 µg/g) and iron (≤ 100 µg/day PDE). The terminal drug substances—danoprevir sodium registered under CNDA as Ganovo® and glecaprevir formulated as the pibrentasvir co-formulation Mavyret®—depend on the (3S,4S)-aminohydroxypyrrolidine building block as a starting material whose stereochemical integrity directly governs the impurity profile of the finished dosage form.
When stereochemical integrity during Boc removal determines batch failure rates in Alzheimer’s-targeted BACE1 modulatorsFor β-site amyloid precursor protein cleaving enzyme 1 modulators such as elenbecestat (E2609)—and structurally related spirocyclic or fused pyrrolidine chemotypes evaluated in Phase II/III trials—the (3S,4S)-3-amino-4-hydroxypyrrolidine intermediate provides the rigid hydrogen-bond-donor scaffold that docks into the S1′–S2′ subsite. The downstream sequence typically routes through an N-alkylation or reductive amination: a pre-formed aldehyde or ketone fragment is condensed with the deprotected (3S,4S)-pyrrolidine free base in tetrahydrofuran at −15 °C, followed by addition of sodium triacetoxyborohydride at a mole ratio of 1.0–1.2 equivalents of the amine relative to the carbonyl substrate. The conversion is monitored by on-line ReactIR for disappearance of the C=O stretch at ≈1720 cm⁻¹; residual amine is back-titrated with ethanolic HCl, and the crude is subjected to flash chromatography on unbonded silica with ethyl acetate/methanol 95:5 to remove the formed boronate adducts. A critical failure mode arises during the preceding Boc deprotection when inadequate acid concentration or elevated temperature permits C-4 epimerization via an oxazolidinone intermediate; the resulting (3R,4R)-diastereomer shows IC₅₀ values 100- to 500-fold weaker against BACE1 in FRET-based substrate assays (commercial kits using Mca-SEVNLDAEFR-K(Dnp)-NH₂). Consequently, batch release includes specific optical rotation testing at 589 nm and 20 °C on a 0.1 dm cell, with a specification of [α]D²⁰ = +25° to +28° (c 1, methanol), a value that deviates precipitously when diastereomeric excess drops below 98%. Equipment for commercial-scale Boc cleavage employs a Hastelloy C-22 reactor with a submerged dip pipe for HCl gas sparging and a jacket capable of sustaining −10 °C brine circulation; the off-gas is scrubbed through a packed column containing 10% w/w NaOH to neutralize entrained acid mist before venting. From a regulatory standpoint, intermediates destined for an active IND application must comply with 21 CFR Part 312 and ICH M7 for control of potentially mutagenic impurities—specifically, monitoring of sulfonate ester formation when alcoholic solvents contact methanesulfonic acid used in an alternative deprotection route—and the impurity identification and qualification thresholds set out in ICH Q3A (reporting threshold 0.05%, identification 0.10%, qualification 0.15% for a ≤ 2 g/day dose). The terminal dosage form originally targeted was elenbecestat oral tablets; though clinical development was discontinued, the (3S,4S)-intermediate remains in active procurement for backup programs and for CRO-synthesized BACE1 tool compounds used in academic structural biology consortia.
Chiral Pyrrolidine-Phosphoramidite Ligands and Their Turnover in Asymmetric HydroformylationDeprotection of the (3S,4S)-3-amino-4-hydroxypyrrolidine-1-carboxylic acid *tert*-butyl ester followed by chemoselective O-silylation with tert-butyldimethylsilyl chloride (1.05 eq, imidazole, DMF, 25 °C, 12 h) yields the N-free amino alcohol that is converted into a phosphoramidite ligand by treatment with 1.1 molar equivalents of phosphorus trichloride in the presence of triethylamine under rigorously anhydrous Schlenk conditions (argon atmosphere, glovebox O₂ ≤ 2 ppm, solvent dried over Na/benzophenone and distilled). The resulting bis(pyrrolidine)-phosphoramidite, once coordinated to a rhodium(I) precursor such as Rh(acac)(CO)₂, drives the asymmetric hydroformylation of vinyl arenes with a turnover frequency exceeding 1500 h⁻¹ at 10 bar syngas (CO/H₂ 1:1) and 60 °C, delivering branched aldehydes with regioselectivity (b/l) ratios above 20 and enantiomeric excess 91–94% consistently across a range of substituted styrenes; the ligand-to-rhodium ratio is maintained at 4:1 to suppress catalyst decomposition to inactive rhodium clusters. Unreacted pyrrolidine intermediate recovered from the ligand synthesis aqueous wash is repurified via distillation under reduced pressure (85–90 °C head temperature at 0.5 mbar) and reused for subsequent batches, consistent with the resource-efficiency expectations under the REACH regulation. Compliance for the metal-containing ligand product intended for export is evidenced by a certificate of analysis reporting rhodium residue below the 10 mg/kg threshold set by internal specification and the absence of Class 1 solvents. The terminal commercial outputs are high-value chiral aldehydes—intermediates for non-steroidal anti-inflammatory agents and fragrance molecules—produced on a multi-kilogram scale using this ligand class in continuous stirred-tank reactor cascades. As a conformationally restricted proline surrogate in fragment-based drug discovery and solid-phase peptide synthesis, the (3S,4S)-3-amino-4-hydroxypyrrolidine scaffold introduces a turn-inducing residue whose backbone torsion angles (φ ≈ −60°, ψ ≈ −30° in a type VI β-turn mimic) are exploited to rigidify glycine-rich loops in target peptides. When deployed in Fmoc-based SPPS on a 2-chlorotrityl chloride resin (loading 1.2 mmol/g), the N-Boc protecting group remains orthogonal to the Fmoc removal conditions: the Fmoc group is cleaved with 20% piperidine/DMF (2 × 10 min) while the Boc group stays intact until final peptide cleavage and global deprotection with 95% trifluoroacetic acid/2.5% triisopropylsilane/2.5% water. Coupling of the (3S,4S)-pyrrolidine building block—typically activated as the HOBt active ester generated in situ with HATU and N,N-diisopropylethylamine—is performed using 3.0 equivalents relative to the resin substitution, with a double-coupling protocol (2 × 60 min) followed by capping with acetic anhydride/pyridine to block any unreacted sites. The hydroxyl group in the 4-position requires temporary protection as the silyl ether when the downstream sequence includes strong bases that could initiate backbone cyclization; alternatively, on-resin Mitsunobu inversion is avoided because the (3S,4S)-stereochemistry is itself the desired configuration. Purification of the cleaved crude peptides employs reversed-phase HPLC on a C18 column with a 0.1% TFA/acetonitrile gradient, and fractions containing the target peptidomimetic are lyophilized to a powder with residual acetonitrile controlled to ≤ 410 ppm per USP <467>. All cGMP manufacture of the starting resin-bound peptide intermediates adheres to ICH Q7 and the applicable sections of 21 CFR 210/211, while the protected (3S,4S)-pyrrolidine monomer is supplied with a purity of ≥ 99.0% (by qNMR) and total unknown impurities ≤ 0.50%. The terminal products are intrachain-modified peptidomimetics—exemplified by constrained CXCR4 antagonists and macrocyclic protease inhibitor leads—that require this single chiral building block to lock the bioactive conformation without adding steric bulk. |
Competitive 1-Pyrrolidinecarboxylicacid,3-Amino-4-Hydroxy-,1,1-Dimethylethylester,(3S,4S)- prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
When handling the (3S,4S)-3-amino-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester (IUPAC: 1,1-dimethylethyl (3S,4S)-3-amino-4-hydroxypyrrolidine-1-carboxylate), the molecular formula C₉H₁₈N₂O₃ and a molecular weight of 202.25 g·mol⁻¹ define a constrained, vicinal amino-alcohol scaffold protected at the pyrrolidine nitrogen by a tert-butyloxycarbonyl (Boc) group and at the carboxylic acid as a tert-butyl ester. This dual protection strategy renders the molecule amenable to orthogonal deprotection sequences in solid-phase peptide synthesis (SPPS) and solution-phase medicinal chemistry. Commercial certificates of analysis filed under REACH registration numbers for fine chemical intermediates typically report a white to off-white crystalline powder with a melting range of 112–118 °C (decomposition), specific optical rotation [α]D20 of +18.5 to +22.0 (c=1.0, methanol), and a purity by reversed-phase HPLC at 210 nm exceeding 98.0% area, with the sum of unidentified impurities held below 0.5%.What Distinguishes the (3S,4S) Configuration from its Diastereomers in Asymmetric Synthesis?
The substitution pattern imposes a rigid puckered pyrrolidine ring that preorganizes the amino and hydroxyl groups in a syn-orientation. In contrast, the (3R,4R)-enantiomer yields mirror-image spatial vectors, which, when incorporated into peptidomimetic backbones, invert the handedness of turn motifs. The (3S,4R) and (3R,4S) diastereomers place the amine and hydroxy substituents in a trans-relationship, altering hydrogen-bonding geometries and reducing the propensity to form intramolecular oxazolidinone artifacts during carbodiimide-mediated couplings. This is critical in the synthesis of hepatitis C protease inhibitors, where the (3S,4S) stereochemistry has been correlated with a 12-fold increase in enzyme inhibitory potency compared to the trans isomer in a series of macrocyclic peptidomimetics (tested in a FRET-based NS3/4A assay, IC₅₀ values from literature). The specific rotation and chiral HPLC retention time on a Chiralpak AD-H column (4.6 × 250 mm, hexane:ethanol 80:20 v/v, 1.0 mL·min⁻¹) serve as rapid identity checks to prevent cross-contamination with the (3R,4R) inverse, which typically elutes with a separation factor α of 1.22 under these conditions.Chiral Purity and Enantiomeric Excess: Orthogonal Verification Protocols
Ultraviolet detection at 210 nm underreports non-chromophoric diastereomeric amines; therefore, routine lot release couples high-performance liquid chromatography with pre-column derivatization using Marfey’s reagent (Nα-(2,4-dinitro-5-fluorophenyl)-L-alaninamide) in accordance with Ph. Eur. method 2.2.43. The diastereomeric adducts are resolved on a C18 column (3.5 µm, 150 × 4.6 mm) using a gradient of 0.1% trifluoroacetic acid in water and acetonitrile. An acceptance criterion of ≥99.0% enantiomeric excess is set, with a limit of quantitation below 0.1% for the undesired enantiomer. Polarimetric data at the sodium D-line are cross-validated against quantitative ¹H NMR in D₂O with the addition of a chiral shift reagent, (R)-(−)-1,1′-binaphthyl-2,2′-diyl hydrogenphosphate, to resolve enantiomeric signals for the methine proton at δ 4.15 ppm. Batches that fail to meet 99.0% ee by HPLC are rejected for use in regulated steps under ICH Q7 because downstream crystallisation-induced diastereomeric enrichment is not predicted to be robust due to the compound’s moderate solubility (15 mg·mL⁻¹ in ethyl acetate, 2.4 mg·mL⁻¹ in water at 25 °C). The compound is hygroscopic; differential scanning calorimetry (DSC) at a scan rate of 10 K·min⁻¹ under nitrogen purge reveals a broad endotherm starting at 40 °C attributable to water loss, followed by the melt/decomposition endotherm. Consequently, containers must be opened only in a glovebox with a dew point below −35 °C. After exposure to ambient humidity (> 60% RH) for 30 minutes, water uptake measured by Karl Fischer titration (USP <921>, Method Ia) exceeds 1.2% w/w. Pre-drying at 40 °C under vacuum (< 10 mbar) for 6 hours restores water content below 0.3%, but prolonged drying above 50 °C accelerates lactam formation through intramolecular condensation between the free amine and the tert-butyl ester, generating 0.8–1.5% of a six-membered cyclic byproduct detectable by LC-MS.
| Test Parameter | Method | Acceptance Criterion |
| Appearance | Visual (Ph. Eur. 2.2.1) | White to off-white powder |
| Identification (¹H NMR) | Ph. Eur. 2.2.33, 400 MHz, DMSO‑d₆ | Conforms to reference spectrum; key shifts: δ 1.38 (s, 9H), δ 1.42 (s, 9H), δ 3.85–3.93 (m, 2H) |
| Purity (HPLC, 210 nm) | In-house RP‑HPLC, C18, gradient 5–95% MeCN in 0.1% TFA | ≥ 98.0% area |
| Enantiomeric Excess | Chiral HPLC, Chiralpak AD‑H, derivatised (Marfey’s) | ≥ 99.0% |
| Water Content | Karl Fischer (USP <921>) | ≤ 0.5% |
| Residual Solvents | GC‑FID (Ph. Eur. 2.4.24) | Ethyl acetate ≤ 500 ppm, methanol ≤ 3000 ppm |
| Heavy Metals | ICP‑MS (USP <233>) | Pb ≤ 10 ppm, Cd ≤ 2 ppm, As ≤ 2 ppm |